有关转移性非小细胞肺癌的目标疗法的8件事

These treatments may attack cancer cells more effectively than traditional chemotherapy.

Medically Reviewed
靶疗法靶向癌细胞中特定突变。 Getty Images; iStock

转移性非小细胞的治疗中最令人兴奋的进步之一肺癌(NSCLC)是靶向特定变化或突变的药物,这些药物在细胞变成癌症时会发生。这些所谓的“靶向疗法”通常可以更有效地识别和攻击常规化疗,通常具有更少的副作用。这是您需要了解的有关抗癌医学的有前途的进步。

1. Targeted therapies are more precise than standard chemotherapy

“传统的化学疗法旨在杀死任何快速分裂的细胞,这些细胞往往是癌细胞。但是由于他们没有特定的目标,因此它们也杀死了健康的细胞。”爱德华·加隆,医学博士,洛杉矶加州大学洛杉矶分校乔森森综合癌症中心的胸腔肿瘤学计划主任。

另一方面,有针对性的药物针对癌细胞的内部起作用 - 错误的基因编程使它们与正常细胞不同。医生正在更多地了解驱动癌症的NSCLC细胞DNA中的特定突变。Garon博士说:“这些突变使蛋白质发出信号,从而导致癌症的发展和维持。”靶向疗法直接针对这些蛋白质,以阻止癌症扩散。

2.并非所有转移性NSCLC都相同

Doctors once thought NSCLC was one disease. They now understand that NSCLC can be parsed into different genetic or driver mutations that dictate the tumor’s behavior. This has led to the development of more personalizedcancer medicine。加隆解释说:“虽然我们还没有为每位患者使用不同的药物,但我们确实为在其肺癌细胞中共享相同突变的个体组的药物提供了药物。”

NSCLC中最常见的突变可以通过靶向疗法进行治疗,是一种称为表皮生长因子受体(EGFR)的蛋白质异常,该蛋白质有助于细胞生长和分裂。在具有EGFR突变的NSCLC细胞中,生长信号始终亮起,导致这些细胞生长更快。靶向疗法称为EGFR抑制剂有助于阻止该信号。据妇女和尚未吸烟的人和尚未吸烟的人更常见的EGFR突变。American Cancer Society(ACS)。对于在ALK,BRAF,ROS1和NTRK基因中具有突变的患者,也有FDA批准的疗法。这些药物以药丸形式给出,可以在家口服。

3. Targeted therapies are less likely to cause body-wide side effects than chemotherapy

Because targeted therapy doesn’t kill healthy cells like chemotherapy does, it’s less likely to cause hair loss, nausea, and other side effects associated with chemo treatments. “In aggregate, these drugs have been quite well tolerated and tend to cause fewer and less severe side effects than traditional chemotherapy,” says Garon.

4.…但是它们确实会引起一些副作用

“As with any drug, there can be toxicities,” Garon notes. Side effects of targeted therapy will depend on the type of drug, the dose, and your overall health, but the most common ones areskin rashandgastrointestinalsymptoms. Other side effects can include fatigue, flu-like symptoms, sore mouth, headache, loss of appetite, tingling in hands and feet, taste changes, and sleep problems. Your healthcare team can help you manage any side effects you experience during treatment.

5. Targeted drugs aren’t for everyone

“Probably fewer than 20 percent of patients with non-small-cell lung cancer have genetic mutations that are currently targetable by FDA-approved medications,” says Garon. “In addition to approved therapies, however, there are other mutations in non-small-cell cancer for which there are drugs showing real promise in clinical trials.”

As the available targets go up, the percentage of patients with advanced NSCLC who are candidates for this type of treatment will continue to increase.

6. You need to be tested to know if targeted therapy is an option for you

The only way to know if you’re a candidate for a targeted therapy is to undergo genetic testing (also known as genomic testing or molecular profiling). This involves checking for certain gene or chromosomal changes known to occur in NSCLC in a sample of your cancer tissue, and is often done at the same time as your initialbiopsy(using the same tissue sample).

虽然基因测试被认为是转移性NSCLC中的护理标准,但不仅要询问您的医生如果您正在测试您,但正好对哪些突变进行了测试,强调Garon。他说:“您要确保对具有FDA批准疗法的突变进行测试,但也可能尚未批准疗法,但现在有药物在临床试验中显示出希望。”

Comprehensive genetic testing will help you and your doctor determine all your possible treatment choices.

7. Targeted drugs can be expensive

The cost of targeted therapy depends on the drug used, but some can run thousands of dollars per month, according to the ACS. Health insurance plans typically cover at least some of the cost, but each plan is different. Your plan may cover targeted drugs taken by mouth under their prescription drug benefit, rather than their chemotherapy benefit, which may mean you will pay more out of pocket than would for IV drugs given in a hospital or clinic. Before you start treatment, find out how much your insurer will pay for any targeted drug you take. If you need help covering the cost, ask your healthcare team about getting help from the drug company or applying for a copay or prescription drug assistance program.

8.您可能仍然需要其他治疗

EGRF或ALK基因中突变的患者通常将靶向治疗作为第一线治疗。Garon说:“具有其他类型突变的患者有时会采用基于化学疗法的方法,然后转化为靶向疗法。”

Even if you start treatment with a targeted therapy alone, you may need other types of treatment at some point in your cancer journey. “Over time the lung cancer cells may develop a way of continuing to grow despite the drug and the therapy is no longer effective,” Garon explains. When that happens can vary significantly, from several months to several years. When a targeted treatment is no longer effective, you may need to go on chemotherapy or immunotherapy or a combination of the two.

Baidu